About Menactra Vaccine
Menactra vaccine booster dose has proven immunogenicity
- >99% of trial participants achieved protective antibody levels (SBA-Ha titers ≥1:8)1
- ≥95% of trial participants achieved a ≥4-fold rise in SBA-H titer1
- Menactra vaccine provides protection against invasive meningococcal disease from 4 vaccine-preventable serogroups (A, C, Y, and W-135)1
Five serogroups, A, B, C, Y, and W-135, are responsible for almost all cases of meningococcal disease worldwide2
- Menactra vaccine booster injection was shown to be safe1
The most common solicited injection site and systemic reactions within 7 days after booster vaccination were pain and myalgia. Other adverse reactions may occur.
Overall rates of solicited injection site reactions and solicited systemic reactions were similar to those observed in adolescents and adults receiving a primary dose of Menactra vaccine in previous studies.
A robust immune response in adolescents after the primary dose1
- The immunogenicity of Menactra vaccine has been proven in clinical trials — and confirmed in everyday use
- Adolescents achieved robust immune responses after receiving a primary dose
Menactra vaccine has a long-established record of safety
Over 78 million doses of Menactra vaccine have been distributed,3 and more than 52,000 infants, children, adolescents, and adults have been included in 29 clinical trials.4-6
aSBA-H = serum bactericidal assay using human complement.Ordering Menactra vaccine at VaccineShoppe.com is easy.
IMPORTANT SAFETY INFORMATION FOR MENACTRA VACCINE
Menactra vaccine is contraindicated in persons with a known hypersensitivity (eg, anaphylaxis) to any component of the vaccine.
Persons previously diagnosed with Guillain-Barré syndrome (GBS) may be at increased risk of GBS following receipt of Menactra vaccine. GBS has been reported in temporal relationship following administration of Menactra vaccine. The decision to give Menactra vaccine should be based on careful consideration of the potential benefits and risks.
Syncope (fainting) can occur in association with administration of injectable vaccines, including Menactra vaccine. Procedures should be in place to prevent falling injury and manage syncopal reactions.
The most common local and systemic adverse reactions to Menactra vaccine include pain, redness, and swelling at the injection site and appetite loss (all age groups); induration at the injection site and diarrhea (all age groups except infants); irritability and drowsiness (infants and children); abnormal crying, vomiting, and fever (infants); headache, fatigue, malaise, and arthralgia (adolescents and adults). Other adverse reactions may occur. Vaccination with Menactra vaccine may not protect all individuals.
INDICATION FOR MENACTRA VACCINE
Menactra vaccine is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. Menactra vaccine is approved for use in individuals 9 months through 55 years of age. Menactra vaccine does not prevent N meningitidis serogroup B disease.
Before administering Menactra vaccine, please see accompanying full Prescribing Information.
- 1. Menactra vaccine [Prescribing Information]. Swiftwater, PA: Sanofi Pasteur Inc.; 2016.
- 2. Hamborsky J, Kroger A, Wolfe S, eds. Meningococcal disease. In: Hamborsky J, Kroger A, Wolfe S, eds. Epidemiology and Prevention of Vaccine-Preventable Diseases. 13th ed. Washington DC: Public Health Foundation; 2015:231-246.
- 3. Sanofi Pasteur Inc. Data on File (Menactra vaccine total doses distributed since 2005), November 15, 2016. MKT31596.
- 4. Sanofi Pasteur Inc. Data on File (Menactra vaccine clinical development overview), November 2012. MKT25824.
- 5. Sanofi Pasteur Inc. MTA57: Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered as a 2-Dose Schedule to Children. https://clinicaltrials.gov/ct2/show/NCT01689155. Accessed March 16, 2017.
- 6. Sanofi Pasteur Inc. Data on File (safety and immunogenicity of a single dose of Menactra® vaccine 4-6 years after prior Menactra vaccine), December 2014. MKT28756.
- 7. US Food and Drug Administration. Approval letter. April 22, 2011. http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm252511.htm. Accessed March 16, 2017.
- 8. US Food and Drug Administration. Approval letter. October 18, 2007. http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm131174.htm. Accessed March 16, 2017.
- 9. US Food and Drug Administration. Approval letter. January 14, 2005. http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm131181.htm. Accessed March 16, 2017.
- 10. US Food and Drug Administration. Approval letter. September 4, 2014. http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm413177.htm. Accessed March 16, 2017.